Oruka Therapeutics, Inc.
ORKA
$14.51
-$0.925-5.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.57M | -21.00M | -33.39M | -28.62M | -22.24M |
| Total Depreciation and Amortization | 19.00K | 16.00K | 18.50K | 11.00K | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.70M | 3.15M | 4.26M | 10.53M | 689.00K |
| Change in Net Operating Assets | -2.29M | -3.03M | 5.03M | -9.73M | 10.52M |
| Cash from Operations | -23.15M | -20.87M | -24.08M | -27.82M | -11.03M |
| Capital Expenditure | -34.00K | -13.00K | -35.20K | -171.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4.89M | 42.88M | -359.93M | -- | -- |
| Cash from Investing | 4.86M | 42.87M | -359.97M | -171.00K | -- |
| Total Debt Issued | -- | -- | -414.94M | 417.21M | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 109.00K | -- | 454.57M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 266.50K | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 449.10K | 6.53M | -1.59M |
| Cash from Financing | 109.00K | -- | 40.34M | 423.74M | -1.59M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.18M | 22.00M | -343.70M | 395.75M | -12.62M |